CUA Educational Content

Latest Practice-Changing Evidence, Unveiling Cutting-Edge Insights for the Treatment of Early and Advanced Stage Renal Cell Carcinoma

Speaker: Daniel Heng, Aly-Khan Lalani, Michel Pavic & Ricardo Rendon


By participating in this learning program, healthcare providers can expect to:

  • Summarize the latest practice-changing evidence for the treatment of patients with early and advanced stage renal cell carcinoma
  • Unravel the intricacies of managing renal cell carcinoma
  • Discuss potential side effects and uncover state-of-the-art strategies to effectively manage novel combination therapies in advanced renal cell carcinoma, ensuring optimal patient outcomes


This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.


This program has received financial support in the form of an educational grant from Merck.